# Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo

> **NCT04521296** · PHASE2,PHASE3 · TERMINATED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 432 (actual)

## Conditions studied

- Mild to Moderate COVID-19

## Interventions

- **OTHER:** Part 1
- **OTHER:** Part 2

## Key facts

- **NCT ID:** NCT04521296
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-11
- **Primary completion:** 2021-09-14
- **Final completion:** 2022-03-18
- **Target enrollment:** 432 (ACTUAL)
- **Why stopped:** Changes in drug development plans
- **Last updated:** 2022-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04521296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04521296, "Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04521296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*